Movement is medicine in multiple myeloma: exercise-boosted immune and metabolic signals linked to treatment response
Official title: Movement is medicine in multiple myeloma: elucidating exercise-mediated immune and metabolic biomarkers that predict treatment response in the bone marrow tumor microenvironment
Funded at Roswell Park Cancer Institute Corp · NIH-11366341 · Data updated 2026-11-12
A study will look at how exercise changes immune and metabolic markers in the bone marrow of people with multiple myeloma to see if these changes predict how well treatment works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $718,490 |
| NIH project number | 1R01CA304003-01A1 |
| Project ID | NIH-11366341 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with multiple myeloma undergoing therapy who are able to participate in an exercise program.
✕Less likely to help
Patients unable to participate in exercise or with contraindications to physical activity may not benefit.
What this research studies
This project will enroll people with multiple myeloma to undergo an exercise program during their treatment. Researchers will collect bone marrow and blood samples before and after the exercise period to measure immune and metabolic biomarkers. The goal is to connect changes in these biomarkers within the tumor environment to better predict treatment outcomes. The study uses a multi-omics approach to examine how physical activity may influence cancer control at the tissue level.
Why it matters
Potential benefit: If successful, the findings could help tailor exercise and treatment plans to improve cancer control and patient well-being.
How similar studies have gone: Animal studies suggest exercise can modulate the tumor environment, but direct human data are limited and this study aims to provide that.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Cannioto, Rikki — Roswell Park Cancer Institute Corp
- Study coordinator: Cannioto, Rikki
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.